The success of NIPRO’s biosimilar product, launched in late 2023, has exceeded expectations and gained significant market ...

Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug ...

Will significantly enhance service to researchers and institutions across China.

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...

Alcami Corporation, a contract development and manufacturing organization (CDMO), has appointed pharmaceutical industry ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.

New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...

The project is set to become the largest GMP temperature-controlled facility fully dedicated to the life sciences sector in ...